OncoMatch/Clinical Trials/NCT06712316
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Is NCT06712316 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2/3 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Pumitamig · Pembrolizumab · Carboplatin · Pemetrexed · Paclitaxel — This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Prior therapy
Cannot have received: platinum-based chemotherapy
Previous chemotherapy (platinum-based) ... in either neoadjuvant/adjuvant or locally advanced/metastatic setting
Cannot have received: anti-PD-1 therapy
Previous ... PD(L)-1 for treating NSCLC in either neoadjuvant/adjuvant or locally advanced/metastatic setting
Cannot have received: anti-PD-L1 therapy
Previous ... PD(L)-1 for treating NSCLC in either neoadjuvant/adjuvant or locally advanced/metastatic setting
Cannot have received: anti-VEGF monoclonal antibody
prior treatment with anti-VEGF monoclonal antibody
Cannot have received: PD(L)-1/VEGF bispecific antibody
prior treatment with ... PD(L)-1/VEGF bispecific antibody
Lab requirements
Blood counts
Adequate organ function as defined in the protocol
Kidney function
Adequate organ function as defined in the protocol
Liver function
Adequate organ function as defined in the protocol
Adequate organ function as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology · Birmingham, Alabama
- Alaska Oncology and Hematology, LLC · Anchorage, Alaska
- John Muir Clinical Research Center · Concord, California
- University Of California - San Diego Moores Cancer Center · La Jolla, California
- Clermont Oncology Center · Clermont, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06712316 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify